Market Research Report: Mallinckrodt Pharmaceuticals
Company Overview
Name: Mallinckrodt Pharmaceuticals
Mission: Listening for needs. Delivering solutions.
Founded: 1867 by Gustavo, Otto, and Edward Mallinckrodt
Key People: Siggi Olafsson, President and Chief Executive Officer
Headquarters: College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, Ireland
Number of Employees: No information is available
Revenue: No information is available
Known For: Mallinckrodt specializes in the development, manufacturing, marketing, and distribution of specialty pharmaceutical products and therapies. The company focuses on autoimmune diseases, rare diseases, immunotherapy, and critical care therapies among others.
Products
Product Portfolio:
- TERLIVAZ® (terlipressin) for Injection:
- Description: First and only FDA-approved product to improve kidney function in adults with Hepatorenal Syndrome (HRS) that involves a rapid reduction in kidney function.
- Key Features:
- Administered at a dose of 1 mg every six hours for up to 14 days, can escalate to 2 mg on Day 4 if necessary.
- Key target in addressing acute and life-threatening renal conditions in patients with advanced liver disease.
- Acthar® Gel:
- Description: Repository corticotropin injection used for an array of conditions.
- Key Features: Available in various dosages, including multi-dose vials and pre-filled injectors.
Note: The above-mentioned products are part of a larger portfolio that addresses various areas such as neurology, rheumatology, nephrology, pulmonology, ophthalmology, oncology, and gastrointestinal disorders.
Recent Developments
News and Events
- Jefferies London Healthcare Conference (Nov 19, 2024):
- Mallinckrodt's CEO, Siggi Olafsson, will present at this prestigious event.
- Therakos Business Divestiture (Dec 2, 2024):
- Completion of the sale of its Therakos business to CVC Capital Partners Fund IX for $925 million.
- The transaction will aid in optimizing the company’s capital structure by reducing net debt by over 60%.
Research and Innovations
- Presentation at AASLD Annual Meeting (Nov 18, 2024):
- Mallinckrodt presents on TERLIVAZ® focusing on its effectiveness after 12 doses for HRS patients.
Strategic Moves
- Sustainability Report 2023:
- Highlights efforts in advancing sustainability practices.
- Commitment to Diversity, Equity, and Inclusion:
- Emphasizes a corporate culture strengthened through diverse identities and experiences.
Summary
Mallinckrodt Pharmaceuticals has maintained a strategic focus through its expansive product portfolio aimed at treating autoimmune and rare diseases. With recent events like the presentation of TERLIVAZ® and the divestiture of Therakos, the company continues to refine its focus towards its core capabilities in specialty pharmaceuticals.
The strategic movement towards reducing debt through business sales and a focus on significant R&D efforts delineates Mallinckrodt's commitment to both patient care and shareholder value. As evidenced in upcoming events and past achievements, Mallinckrodt positions itself as a frontrunner in specialty pharmaceutical innovation with a solid base for continued growth and adaptation in the healthcare sector.
For further inquiries, stakeholders and investors are directed towards the Investor Relations page for the latest announcement and strategic updates from Mallinckrodt Pharmaceuticals.
